Skip to main content
. 2022 May 21;111:135–147. doi: 10.1016/j.reprotox.2022.05.012

Fig. 6.

Fig. 6

Impact of remdesivir (RDV) on the epiblast (EPI) and the primitive endoderm (PrE) cells. Embryos are treated with indicated concentrations of RDV from E2.5 to E4.5, and immunohistochemically examined for SOX2 (EPI marker), NANOG (EPI marker), SOX17 (PrE marker), and GATA4 (PrE marker). A. Representative images of embryos that are stained for the nuclei (DAPI), SOX2 (green) and SOX17 (red). B. Representative images of embryos stained for the nuclei (DAPI), NANOG (green) and GATA4 (red). Scale bars = 50 µm. C. Numbers of nuclei that are positive for the EPI marker and PrE marker per embryo. Red lines indicate mean values (n = 19 or 20 for each treatment group). Statistically significant differences are marked with horizontal bars and p-values (t-test) between two groups.